These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6882547)

  • 1. [Evaluation of the pseudocholinesterase activity in hyperlipoproteinemia type II and type IV].
    Averna MR; Montalto G; Rini GB; Di Fede G; Labisi M; Marino G; Notarbartolo A
    Boll Soc Ital Biol Sper; 1983 Apr; 59(4):520-4. PubMed ID: 6882547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Further studies on the activity of fatty acid lecithin acyltransferase in patients with type II and IV hyperlipoproteinemia].
    Kuczyńska K; Sznajderman M
    Pol Arch Med Wewn; 1980 Oct; 64(4):335-40. PubMed ID: 7454597
    [No Abstract]   [Full Text] [Related]  

  • 3. [Lipoprotein lipase activity of ischemic heart disease patients with different types of hyperlipoproteinemia on the basis of fat loading].
    Nikul'cheva NG; Soliternova IB; Krivoruchenko IV
    Vopr Med Khim; 1980; 26(6):808-13. PubMed ID: 7456412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
    Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased level of the complement C3 protein in endogenous hypertriglyceridemia.
    Uza G; Cristea A; Cucuianu MP
    J Clin Lab Immunol; 1982 Jun; 8(2):101-5. PubMed ID: 7108936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J; Martorell J
    Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of phenofibrate on serum cholesterol and triglyceride concentration in patients with primary hyperlipoproteinemia].
    Cieślicka T; Paradowski S
    Pol Arch Med Wewn; 1983; 70(5-6):223-9. PubMed ID: 6677885
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cholesterol and triglyceride plasma levels in patients with primary hyperlipoproteinemia. Decline after short-term i.v. glucagon administration].
    Andĕl M; Brodan V; Kucerová L; Grafnetter D; Kuhn E; Veselková A
    Cas Lek Cesk; 1980 May; 119(22):616-21. PubMed ID: 7427980
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperlipoproteinemia, HDL-cholesterol and arteriosclerosis indices].
    Herrmann W; Reuter W
    Z Gesamte Inn Med; 1982 Dec; 37(24):830-3. PubMed ID: 6963524
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro effect of p-chlormercuribenzoate upon dilute blood clot lysis time in hyperlipemia.
    Cucuianu MP; Stef C; Zdrenghea D; Popescu O
    Thromb Haemost; 1979 Oct; 42(3):929-44. PubMed ID: 505407
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of bezamidine on plasma cholesterol and triglyceride levels in patients with familial hyperlipoproteinemia].
    Kukharchuk VV; Koshechkin VA; Konovalov GA; Rozhkova TA; Solov'eva EIu
    Kardiologiia; 1990 Dec; 30(12):16-8. PubMed ID: 2097388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fatty acid metabolism in primary hyperlipoproteinemia].
    Reuter W
    Z Gesamte Inn Med; 1979 Oct; 34(20):suppl 287-9. PubMed ID: 398634
    [No Abstract]   [Full Text] [Related]  

  • 18. Early and late results of coronary artery bypass in patients with hyperlipoproteinemia.
    Hanson EC; Levine FH; Adzick NS; Lees RS; Daggett WM; Austen WG; Buckley MJ
    J Thorac Cardiovasc Surg; 1980 Mar; 79(3):372-80. PubMed ID: 6965512
    [No Abstract]   [Full Text] [Related]  

  • 19. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J; Vinzia C; Gómez JM; Morató J
    Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum electrophoretic lipoprotein factors and pseudocholinesterase activity in thyroid disease.
    Vlaicu R; Popescu E; Popescu TA; Cucuianu M
    Endocrinologie; 1978; 16(2):147-51. PubMed ID: 209530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.